Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHA NASDAQ:CGEN NASDAQ:DTIL OTCMKTS:OSIR NASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHAAthira Pharma$3.74$3.93$2.20▼$8.26$14.75M3.0147,922 shs23,571 shsCGENCompugen$2.11-5.8%$1.51$1.13▼$2.66$199.89M2.61460,839 shs1.17 million shsDTILPrecision BioSciences$5.85+5.2%$5.01$3.61▼$9.20$65.54M1.7287,543 shs98,553 shsOSIROsiris Therapeutics$18.99$18.99$7.01▼$19.30$655.69MN/A205,753 shsN/ASLDBSolid Biosciences$6.23+3.7%$5.77$2.41▼$7.37$467.99M2.531.35 million shs630,944 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHAAthira Pharma0.00%-3.11%+3.89%-2.63%-15.19%CGENCompugen-5.80%+19.89%+57.46%+33.54%+25.60%DTILPrecision BioSciences+5.22%+2.99%+26.90%+29.42%-34.34%OSIROsiris Therapeutics0.00%0.00%0.00%0.00%0.00%SLDBSolid Biosciences+3.66%+12.86%+15.58%+11.65%+1.96%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHAAthira Pharma$3.74$3.93$2.20▼$8.26$14.75M3.0147,922 shs23,571 shsCGENCompugen$2.11-5.8%$1.51$1.13▼$2.66$199.89M2.61460,839 shs1.17 million shsDTILPrecision BioSciences$5.85+5.2%$5.01$3.61▼$9.20$65.54M1.7287,543 shs98,553 shsOSIROsiris Therapeutics$18.99$18.99$7.01▼$19.30$655.69MN/A205,753 shsN/ASLDBSolid Biosciences$6.23+3.7%$5.77$2.41▼$7.37$467.99M2.531.35 million shs630,944 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHAAthira Pharma0.00%-3.11%+3.89%-2.63%-15.19%CGENCompugen-5.80%+19.89%+57.46%+33.54%+25.60%DTILPrecision BioSciences+5.22%+2.99%+26.90%+29.42%-34.34%OSIROsiris Therapeutics0.00%0.00%0.00%0.00%0.00%SLDBSolid Biosciences+3.66%+12.86%+15.58%+11.65%+1.96%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHAAthira Pharma 1.00Sell$4.006.95% UpsideCGENCompugen 2.00Hold$4.0089.57% UpsideDTILPrecision BioSciences 2.33Hold$47.00703.42% UpsideOSIROsiris Therapeutics 0.00N/AN/AN/ASLDBSolid Biosciences 2.92Moderate Buy$15.00140.77% UpsideCurrent Analyst Ratings BreakdownLatest DTIL, CGEN, SLDB, OSIR, and ATHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ATHAAthira PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CGENCompugenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025DTILPrecision BioSciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025SLDBSolid BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ATHAAthira PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CGENCompugenWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025DTILPrecision BioSciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SLDBSolid BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/19/2025ATHAAthira PharmaMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$4.008/14/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.008/14/2025SLDBSolid BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$15.00 ➝ $13.00(Data available from 10/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHAAthira PharmaN/AN/AN/AN/A$11.60 per shareN/ACGENCompugen$27.86M6.76N/AN/A$0.62 per share3.40DTILPrecision BioSciences$68.70M1.00N/AN/A$6.87 per share0.85OSIROsiris TherapeuticsN/AN/AN/AN/AN/AN/ASLDBSolid Biosciences$8.09M59.97N/AN/A$3.43 per share1.82Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHAAthira Pharma-$96.94M-$15.50N/AN/AN/AN/A-139.40%-106.84%11/6/2025 (Estimated)CGENCompugen-$14.23M-$0.22N/AN/AN/A-87.45%-34.77%-16.82%11/11/2025 (Estimated)DTILPrecision BioSciences$7.17M-$8.81N/AN/AN/A-6,205.79%-176.47%-69.05%11/3/2025 (Estimated)OSIROsiris TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/ASLDBSolid Biosciences-$124.70M-$2.80N/AN/AN/AN/A-69.70%-56.74%11/5/2025 (Estimated)Latest DTIL, CGEN, SLDB, OSIR, and ATHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025CGENCompugen-$0.09N/AN/AN/A$1.47 millionN/A11/6/2025Q3 2025ATHAAthira Pharma-$0.17N/AN/AN/AN/AN/A11/5/2025Q3 2025SLDBSolid Biosciences-$0.42N/AN/AN/AN/AN/A11/3/2025Q3 2025DTILPrecision BioSciences-$0.31N/AN/AN/AN/AN/A8/12/2025Q2 2025SLDBSolid Biosciences-$0.51-$0.42+$0.09-$0.42N/AN/A8/7/2025Q2 2025ATHAAthira Pharma-$1.80-$1.80N/A-$0.18N/AN/A8/7/2025Q2 2025DTILPrecision BioSciences-$0.09-$2.13-$2.04-$2.13$6.27 million$0.02 million8/6/2025Q2 2025CGENCompugen-$0.07-$0.08-$0.01-$0.08$3.95 million$1.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHAAthira PharmaN/AN/AN/AN/AN/ACGENCompugenN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/AOSIROsiris TherapeuticsN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHAAthira PharmaN/A10.8110.81CGENCompugenN/A4.744.74DTILPrecision BioSciences0.665.185.18OSIROsiris TherapeuticsN/AN/AN/ASLDBSolid BiosciencesN/A9.349.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHAAthira Pharma57.12%CGENCompugen12.22%DTILPrecision BioSciences37.99%OSIROsiris Therapeutics0.28%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipATHAAthira Pharma19.80%CGENCompugen9.50%DTILPrecision BioSciences4.00%OSIROsiris Therapeutics43.40%SLDBSolid Biosciences13.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHAAthira Pharma403.94 million3.16 millionOptionableCGENCompugen7089.24 million80.76 millionOptionableDTILPrecision BioSciences20011.79 million11.32 millionNo DataOSIROsiris Therapeutics34234.53 millionN/ANot OptionableSLDBSolid Biosciences10077.87 million67.26 millionOptionableDTIL, CGEN, SLDB, OSIR, and ATHA HeadlinesRecent News About These CompaniesSolid Biosciences (NASDAQ:SLDB) Upgraded at Wall Street ZenOctober 11, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Receives "Sell (D-)" Rating from Weiss RatingsOctober 9, 2025 | marketbeat.comSolid Biosciences (NASDAQ:SLDB) Trading 22% Higher - Time to Buy?October 8, 2025 | marketbeat.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2025 | globenewswire.comSolid Biosciences to Present at Upcoming Scientific MeetingsOctober 1, 2025 | globenewswire.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Buy" by BrokeragesSeptember 29, 2025 | marketbeat.comSolid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific MeetingSeptember 25, 2025 | globenewswire.comGoldman Sachs Group Inc. Buys 43,910 Shares of Solid Biosciences Inc. $SLDBSeptember 25, 2025 | marketbeat.comKinea Bio Secures $1.1M Jain Foundation Investment and Solid Biosciences Capsid License to Advance Novel Gene Therapy for Dysferlinopathy, a Rare Neuromuscular DiseaseSeptember 23, 2025 | finance.yahoo.comSolid Biosciences announces licensing agreement with Kinea BioSeptember 23, 2025 | msn.comSolid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101September 23, 2025 | globenewswire.comSolid Biosciences (NASDAQ:SLDB) Stock Rating Lowered by Wall Street ZenSeptember 15, 2025 | marketbeat.comSolid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comSolid Biosciences to Participate at Upcoming Investor ConferencesAugust 28, 2025 | globenewswire.comSolid Biosciences Inc.: Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 13, 2025 | finanznachrichten.deSolid Biosciences reports Q2 EPS (42c), consensus (49c)August 12, 2025 | msn.comSolid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 12, 2025 | globenewswire.comBrutal 2025 for Sarepta—Analysts Still Call for 179% Upside (SLDB)...August 12, 2025 | marketbeat.comSolid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 1, 2025 | globenewswire.comSolid Bio Green on Fast Track NodJuly 23, 2025 | baystreet.caSolid Biosciences Receives FDA Fast Track Designation for SGT-501 First-in-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)July 23, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDTIL, CGEN, SLDB, OSIR, and ATHA Company DescriptionsAthira Pharma NASDAQ:ATHA$3.74 0.00 (0.00%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$3.72 -0.03 (-0.67%) As of 10/14/2025 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Compugen NASDAQ:CGEN$2.11 -0.13 (-5.80%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$2.07 -0.04 (-1.90%) As of 10/14/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Precision BioSciences NASDAQ:DTIL$5.85 +0.29 (+5.22%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$5.88 +0.03 (+0.58%) As of 10/14/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Osiris Therapeutics OTCMKTS:OSIR$18.99 0.00 (0.00%) As of 04/17/2019Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.Solid Biosciences NASDAQ:SLDB$6.23 +0.22 (+3.66%) Closing price 10/14/2025 04:00 PM EasternExtended Trading$6.13 -0.10 (-1.67%) As of 10/14/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Healthcare Companies Insiders Are Buying NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 3 Dividend Hikes That Signal Renewed Strength in 2025 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
